Regeneron Pharmaceuticals Inc. buy PapaSmurf
Start price
19.10.19
/
50%
€268.00
Target price
19.12.19
-
Performance (%)
25.13%
End price
19.12.19
€335.35
Summary
This prediction ended on 19.12.19 with a price of €335.35. The prediction had a final performance of 25.13%. PapaSmurf has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -6.644% | -6.644% | -20.241% | -16.379% |
| iShares Core DAX® | 1.659% | 1.586% | 18.113% | 65.562% |
| iShares Nasdaq 100 | 0.381% | 1.900% | 8.877% | 103.178% |
| iShares Nikkei 225® | 2.102% | -1.377% | 13.281% | 43.551% |
| iShares S&P 500 | 0.221% | 1.258% | 3.556% | 63.162% |
Comments by PapaSmurf for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Buy Regeneron Pharmaceuticals Inc.